{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:16:11Z","timestamp":1793610971863,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006114","name":"Saxony State Ministry of Science and Art","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtct.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:31:06Z","timestamp":1752679866000},"page":"789-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2053-3857","authenticated-orcid":false,"given":"Thomas C.","family":"Wiemers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Ferle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Ader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sotikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4014-6030","authenticated-orcid":false,"given":"David","family":"Fandrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Grieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8463-5179","authenticated-orcid":false,"given":"Patrick","family":"Born","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6045-3349","authenticated-orcid":false,"given":"Heike","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Yau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8239-002X","authenticated-orcid":false,"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-7476","authenticated-orcid":false,"given":"Marco","family":"Herling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Heyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6999-5024","authenticated-orcid":false,"given":"Thomas","family":"Neumuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Jonas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jtct.2025.07.003_bib0001","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41375-023-02129-y","article-title":"Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed\/refractory myeloma","volume":"38","author":"Fischer","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.003_bib0002","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/bloodadvances.2023011767","article-title":"Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality","volume":"8","author":"Rejeski","year":"2024","journal-title":"Blood Adv"},{"issue":"24","key":"10.1016\/j.jtct.2025.07.003_bib0003","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/bloodadvances.2022008320","article-title":"Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma","volume":"6","author":"Logue","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.07.003_bib0004","article-title":"Prolonged hematological toxicity in patients receiving BCMA\/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.003_bib0005","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.003_bib0006","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.003_bib0007","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.07.003_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.jtct.2025.07.003_bib0009","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41409-023-01968-8","article-title":"Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis","volume":"58","author":"Luther","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.07.003_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1065716","article-title":"Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer","volume":"12","author":"Zeng","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.003_bib0011","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.acra.2022.06.013","article-title":"Splenic size and volume measurements in patients with chronic lymphocytic leukemia","volume":"30","author":"Ogunleye","year":"2023","journal-title":"Acad Radiol"},{"issue":"12","key":"10.1016\/j.jtct.2025.07.003_bib0012","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdq621","article-title":"Splenic volume can be a novel predictive parameter for the prognosis of chronic lymphocytic leukemia?","volume":"21","author":"Song","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.003_bib42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ymthe.2019.10.007","article-title":"Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene","volume":"28","author":"Sellmyer","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2025.07.003_bib0013","series-title":"Splenomegaly","author":"Chapman","year":"2025"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.003_bib0021","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.003_bib0015","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.07.003_bib0016","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.003_bib0017","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12885-020-07317-y","article-title":"Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma","volume":"20","author":"Song","year":"2020","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2025.07.003_bib0018","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.07.003_bib0019","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy","author":"Rejeski","year":"2025","journal-title":"Blood J"},{"key":"10.1016\/j.jtct.2025.07.003_bib0020","article-title":"How I treat Cytopenias after CAR T-cell therapy","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.07.003_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.658314","article-title":"Advanced flow cytometry assays for immune monitoring of CAR-T cell applications","volume":"12","author":"Blache","year":"2021","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.jtct.2025.07.003_bib0023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/bjc.1988.169","article-title":"Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level","volume":"58","author":"Courdi","year":"1988","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.003_bib0024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2307\/2532740","article-title":"Maximally selected rank statistics","volume":"48","author":"Lausen","year":"1992","journal-title":"Biometrics"},{"issue":"3","key":"10.1016\/j.jtct.2025.07.003_bib0025","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0167-9473(95)00016-X","article-title":"Evaluating the effect of optimized cutoff values in the assessment of prognostic factors","volume":"21","author":"Lausen","year":"1996","journal-title":"Comput Stat Data Anal"},{"issue":"5","key":"10.1016\/j.jtct.2025.07.003_bib0026","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2214\/AJR.23.29478","article-title":"Automated deep learning artificial intelligence tool for spleen segmentation on CT: defining volume-based thresholds for splenomegaly","volume":"221","author":"Perez","year":"2023","journal-title":"Am J Roentgenol"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.003_bib0028","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1007\/s00330-024-11191-8","article-title":"Splenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma","volume":"35","author":"Neelsen","year":"2024","journal-title":"Eur Radiol"},{"issue":"16","key":"10.1016\/j.jtct.2025.07.003_bib0029","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.7150\/thno.33289","article-title":"Lack of Spleen signal on diffusion weighted MRI is associated with high tumor burden and poor prognosis in multiple myeloma: a link to extramedullary hematopoiesis?","volume":"9","author":"Rasche","year":"2019","journal-title":"Theranostics"},{"issue":"13","key":"10.1016\/j.jtct.2025.07.003_bib0030","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.7150\/thno.75847","article-title":"Reduced splenic uptake on68 Ga-Pentixafor-PET\/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis","volume":"12","author":"Kraus","year":"2022","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.003_bib0031","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcyt.2024.08.007","article-title":"Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma","volume":"27","author":"Cheng","year":"2025","journal-title":"Cytotherapy"},{"issue":"8","key":"10.1016\/j.jtct.2025.07.003_bib0032","article-title":"Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells","volume":"4","author":"Strati","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.003_bib0033","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s13287-024-03941-8","article-title":"Mesenchymal stem cell infusion for enhancing hematopoietic recovery and addressing cytopenias in CAR-T cell therapy","volume":"15","author":"Xia","year":"2024","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"10.1016\/j.jtct.2025.07.003_bib0034","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/ajcp\/aqae083","article-title":"Persistent cytopenias after anti-BCMA CAR T-cell therapy are associated with reduced hematopoietic activity in posttreatment bone marrows","volume":"162","author":"Patwardhan","year":"2024","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.jtct.2025.07.003_bib0036","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1515\/rjim-2015-0046","article-title":"Pulmonary extramedullary hematopoiesis mimicking plasmacytoma in a patient with multiple myeloma","volume":"53","author":"Baldane","year":"2015","journal-title":"Romanian J Intern Med Rev Roum Med Interne"},{"issue":"17","key":"10.1016\/j.jtct.2025.07.003_bib0037","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1212\/WNL.0b013e31828f1899","article-title":"Riverol M. Intracranial extramedullary hematopoiesis associated with multiple myeloma","volume":"80","author":"Palma","year":"2013","journal-title":"Neurology"},{"issue":"Suppl. 2","key":"10.1016\/j.jtct.2025.07.003_bib0038","doi-asserted-by":"crossref","first-page":"116","DOI":"10.5301\/tj.5000437","article-title":"Mass-forming extramedullary hematopoiesis in multiple myeloma: 18F-FDG PET\/CT is useful in excluding extramedullary myeloma involvement","volume":"102","author":"Seo","year":"2016","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.jtct.2025.07.003_bib0039","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1073\/pnas.2637010100","article-title":"Shifting foci of hematopoiesis during reconstitution from single stem cells","volume":"101","author":"Cao","year":"2004","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.jtct.2025.07.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201800234","article-title":"Targeting the spleen as an alternative site for hematopoiesis","volume":"41","author":"Short","year":"2019","journal-title":"BioEssays"},{"key":"10.1016\/j.jtct.2025.07.003_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.molimm.2019.06.021","article-title":"Splenomegaly induced by anemia impairs T cell movement in the spleen partially via EPO","volume":"112","author":"Li","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jtct.2025.07.003_bib43","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood.2024024965","article-title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","volume":"10","author":"Freeman","year":"2025","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:33:41Z","timestamp":1772919221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666636725012898"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.07.003","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.31.25321490","asserted-by":"object"}]},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Implications of Splenomegaly in BCMA-Directed CAR T-Cell Therapy for Relapsed Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}